期刊
CANCER
卷 122, 期 19, 页码 3005-3014出版社
WILEY-BLACKWELL
DOI: 10.1002/cncr.30140
关键词
acute myeloid leukemia; allogeneic stem cell transplantation; FMS-like tyrosine kinase 3 (FLT3); 1 more
类别
资金
- Public Health Service grant from the National Cancer Institute (NCI) [5U24-CA076518]
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- NHLIB
- NCI [5U10HL069294]
- Health Resources and Services Administration/Department of Health and Human Services from the Office of Naval Research [HHSH250201200016C, N00014-13-1-0039, N00014-14-1-0028]
- Alexion
- Amgen, Inc
- Be the Match Foundation
- Bristol-Myers Squibb Oncology
- Celgene Corporation
- Chimeric, Inc
- Fred Hutchinson Cancer Research Center
- Gamida Cell Ltd
- Genentech, Inc
- Genzyme Corporation
- Gilead Sciences, Inc
- Health Research, Inc
- Roswell Park Cancer Institute
- HistoGenetics, Inc
- Incyte Corporation
- Jazz Pharmaceuticals, Inc
- Jeff Gordon Children's Foundation
- Leukemia and Lymphoma Society
- Medical College of Wisconsin
- Merck and Company, Inc
- Mesoblast
- Millennium: The Takeda Oncology Company
- Miltenyi Biotec, Inc
- National Marrow Donor Program
- Neovii Biotech NA, Inc
- Novartis Pharmaceuticals Corporation
- Onyx Pharmaceuticals
- Optum Health Care Solutions, Inc
- Otsuka America Pharmaceutical, Inc
- Otsuka Pharmaceutical Company, Ltd-Japan
- Oxford Immunotec
- Perkin Elmer, Inc
- Pharmacyclics
- Sanofi US
- Seattle Genetics
- Sigma-Tau Pharmaceuticals
- Spectrum Pharmaceuticals, Inc
- St Baldrick's Foundation
- Sunesis Pharmaceuticals, Inc
- Swedish Orphan Biovitrum, Inc
- Telomere Diagnostics, Inc
- TerumoBCT
- Therakos, Inc
- University of Minnesota
- Wellpoint, Inc
BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations. Univariate and multivariate analyses revealed an increased risk of relapse at 3 years in the FLT3 mutated group compared with the wild-type (WT) group (38% [95% confidence interval (CI), 30%-45%] vs 28% [95% CI, 24%-33%]; P = .04; relative risk, 1.60 [95% CI, 1.15-2.22]; P = .0048). However, FLT3 mutation status was not significantly associated with nonrelapse mortality, leukemia-free survival, or overall survival. Although more patients in the FLT3 mutated group died from relapsed primary disease compared with those in the WT group (60% vs 46%), the 3-year overall survival rate was comparable for the 2 groups (mutated group: 49%; 95% CI, 40%-57%; WT group: 55%, 95% CI, 50%-60%; P = .20). CONCLUSIONS: The current data indicate that FLT3 mutation status did not adversely impact overall survival after HCT, and about 50% of patients with this mutation who underwent HCT were long-term survivors. (C) 2016 American Cancer Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据